Real world evidence has emerged as one of the most influential developments in modern regulatory science and health technology assessment, reshaping how medicines, medical devices, and innovative therapeutic technologies are evaluated, approved, reimbursed, and monitored across their entire life cycle. Historically, randomized controlled trials have been regarded as the gold standard for determining safety and efficacy, yet their limitations in terms of external validity, cost, duration, and population representativeness have increasingly become apparent in a healthcare environment characterized by rapidly evolving technologies, precision medicine, and complex real world patient populations. Against this backdrop, regulatory agencies, payers, and health systems have turned toward real world data derived from routine clinical practice, insurance claims, patient registries, electronic health records, and digital health tools to supplement and sometimes challenge traditional trial based evidence. This article develops a comprehensive, theoretically grounded, and policy informed analysis of how real world evidence has been institutionalized within regulatory and health technology assessment frameworks, drawing exclusively on the legislative, methodological, and empirical foundations established by the provided references.

The article situates the transformation within the legal and regulatory shift introduced by the 21st Century Cures Act, which explicitly mandated the United States Food and Drug Administration to explore and formalize the use of real world evidence in regulatory decision making, while similar trends have emerged internationally through payer and HTA demands for post marketing and comparative effectiveness evidence. Regulatory guidance documents, performance goals under the Prescription Drug User Fee Act, and FDA frameworks for medical devices have further operationalized this shift, enabling real world data to support label expansions, post approval commitments, and safety monitoring. Industry and academic perspectives emphasize that real world evidence is not merely an adjunct to trials but represents a multidimensional evidence ecosystem capable of addressing questions of effectiveness, heterogeneity of treatment effects, and long term safety that randomized trials alone cannot answer.

Through a detailed methodological and conceptual analysis, this study examines how observational data, pragmatic study designs, and advanced analytical standards are increasingly being aligned with regulatory and HTA expectations. Empirical examples such as the evaluation of antidepressant safety in pregnancy illustrate both the power and the complexity of real world evidence in generating clinically and socially consequential knowledge. At the same time, concerns about bias, confounding, data quality, and transparency continue to challenge the credibility and acceptance of real world studies, necessitating the development of rigorous reporting standards and stakeholder aligned guidance.